SRI-011381-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESRI-011381Cat.No.:HY-100347CASNo.:1629138-41-5分?式:C??H??N?O分?量:329.48作?靶點(diǎn):TGF-beta/Smad作?通路:StemCell/Wnt;TGF-beta/Smad儲(chǔ)存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:50mg/mL(151.75mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.0351mL15.1754mL30.3509mL5mM0.6070mL3.0351mL6.0702mL10mM0.3035mL1.5175mL3.0351mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(protectfromlight)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(7.59mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(7.59mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(7.59mM);ClearsolutionBIOLOGICALACTIVITY?物活性SRI-011381?種有具有?服?物活性的TGF-β信號(hào)通路的激活劑，具有神經(jīng)保護(hù)作?[1]。體外研究SRI-011381(10μM)promotestheproliferationofmouselungfibroblasts,andsignificantlyincreasesTGF-β1,NALP3,collagen-1,andα-SMAexpression[1].體內(nèi)研究SRI-011381(30mg/kg;i.p.;every2d;for22days)partiallyrescuesthedeficitsinopticnerveandretinaofYAPGFAP-CKOEAEmice[2].AnimalModel:YAPGFAP-CKOmicebearingexperimentalautoimmuneencephalomyelitis(EAE)[2]Dosage:30mg/kgAdministration:Intraperitoneallyinjection;every2d;for22daysResult:SignificantlyinhibitedinflammatoryinfiltrationandrelievedthelossofneuronsinYAPGFAP-CKOEAEmice.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Theranostics.2021;11(17):8480-8499.?JCellMolMed.2021Apr;25(7):3272-3283.?LifeSci.2021Aug15;279:119359.?CellCycle.2021Jan26;1-15.?EurJPharmacol.2021Oct5;908:174356.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].JingyinHan,etal.TheImprovementEffectofSodiumFerulateontheFormationofPulmonaryFibrosisinSilicosisMiceThroughtheNeutrophilAlkalinePhosphatase3(NALP3)/TransformingGrowthFactor-β1(TGF-β1)/α-SmoothMuscleActin(α-SMA)Pathway.MedSciMonit.2021Jun15;27:e927978.[2].QianWu,etal.AstrocyticYAPprotectstheopticnerveandretinainanexperimentalautoimmuneencephalomyelitismodelthroughTGF-βsignaling.Theranostics.2021Jul25;11(17):8480-8499.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplicati